LXEO

Lexeo Therapeutics, Inc.

15.93 USD

Last updated Dec 6, 01:17 UTC

Yesterday HIGH

$17.72

Yesterday LOW

$14.79

52w HIGH

$17.72

52w LOW

$9

EPS

1

PE

15.93

Next Earnings

Dec 21, 2023

Overview News Insider Transactions Government Trades

Lexeo Therapeutics, Inc. stock is up 51.71% since 30 days ago. The next earnings date is Dec 21, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.

We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

www.lexeotx.com

Benzinga Insights

Fri Dec 1, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Newsdesk

Tue Nov 28, 2023

Chardan Capital Initiates Coverage On Lexeo Therapeutics with Buy Rating, Announces Price Target of $23

Chardan Capital analyst Geulah Livshits initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announces Price Target of $23.
Benzinga Newsdesk

Tue Nov 28, 2023

Leerink Partners Initiates Coverage On Lexeo Therapeutics with Outperform Rating, Announces Price Target of $19

Leerink Partners analyst Mani Foroohar initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform rating and announces Price Target of $19.
Benzinga Newsdesk

Tue Nov 28, 2023

RBC Capital Initiates Coverage On Lexeo Therapeutics with Outperform Rating, Announces Price Target of $22

RBC Capital analyst Luca Issi initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform rating and announces Price Target of $22.
Benzinga Newsdesk

Tue Nov 28, 2023

Stifel Initiates Coverage On Lexeo Therapeutics with Buy Rating, Announces Price Target of $20

Stifel analyst Paul Matteis initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announces Price Target of $20.
Benzinga Newsdesk

Tue Nov 28, 2023

JP Morgan Initiates Coverage On Lexeo Therapeutics with Overweight Rating, Announces Price Target of $20

JP Morgan analyst Tessa Romero initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight rating and announces Price Target of $20.
Benzinga Newsdesk

Fri Nov 3, 2023

Lexeo Therapeutics Shares Open For Trade At $9.50/Share; IPO Priced At $11/Share
Benzinga Newsdesk

Fri Nov 3, 2023

Lexeo Therapeutics Prices Initial Public Offering Of 9,090,910 Common Shares At $11.00/Share
Benzinga Insights

Thu Nov 2, 2023

Lexeo Therapeutics, Inc To Start Trading Tomorrow

Chardan Capital

Tue Nov 28, 08:18

buy

initial
Leerink Partners

Tue Nov 28, 08:10

buy

initial
RBC Capital

Tue Nov 28, 06:42

buy

initial
Stifel

Tue Nov 28, 06:40

buy

initial
JP Morgan

Tue Nov 28, 05:59

buy

initial

Advanced Data Unlock

Omega Fund VI, L.P., 10% Owner

Tue Nov 7, 2023

LXEO Recent Insider Trades and Stock Chart

454,545 shares bought
McCormac Paul, Chief Technical Officer

Tue Nov 7, 2023

LXEO Recent Insider Trades and Stock Chart

29,061 shares converted
Lundbeckfond Invest A/S, 10% Owner

Tue Nov 7, 2023

LXEO Recent Insider Trades and Stock Chart

227,272 shares bought
Longitude Capital Partners IV, LLC, 10% Owner

Tue Nov 7, 2023

LXEO Recent Insider Trades and Stock Chart

454,545 shares bought